Implantable, self-regulating mechanochemical insulin pump

• US 5,062,841 A
• Filed: 11/14/1989
• Issued: 11/05/1991
• Est. Priority Date: 08/12/1988
• Status: Expired due to Term

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Siegel, Ronald A.
• Primary Examiner(s): Pellegrino, Stephen C.
• Assistant Examiner(s): Rafa, Michael
• Application Number:
  US07/434,623
• Time in Patent Office: 721 Days
• Field of Search: 604/891.1, 604/892.1, 604/131, 604/132, 604/141, 604/151, 604/153, 604/422, 604/423, 604/438, 424/422, 424/423, 424/438
• US Class Current: 604/891.1
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61M 2005/14513 with secondary fluid driving or regulating the infusion
• CPC Class Codes: A61M 31/002 Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50
• CPC Class Codes: C12N 11/087 Acrylic polymers

Abstract

An implantable pump for the delivery of insulin to a mammal has a biocompatible housing which supports an aqueous-swellable glucose-sensitive member and a chamber containing a pharmaceutically acceptable insulin composition. The aqueous-swellable member is exposed to the body fluids which surround the pump when it is implanted; it initiates an insulin pumping cycle by swelling in response to an increase in blood glucose level and terminates an insulin pumping cycle by deswelling in response to the decrease in blood glucose level. When the glucose-sensitive aqueous-swellable member swells in response to an increase in blood glucose level, it generates a hydraulic force which causes insulin composition to be expelled from the chamber through a pressure-sensitive one way valve. The valve seals the chamber when the hydraulic force is withdrawn by deswelling of the glucose-sensitive aqueous-swellable member.

Claims

1. An implantable pump for the delivery of insulin to a mammal in need thereof, said pump comprising a housing which supports within its walls:

(a) an aqueous-swellable member which initiates an insulin pumping cycle by swelling in response to an increase in blood glucose level and terminates an insulin pumping cycle by deswelling in response to a decrease in blood glucose level, said member being exposed to the body fluids which surround the pump when implanted in a mammal;

(b) a first chamber containing a pharmaceutically acceptable insulin composition and including a valve means which permits the outflow of the insulin composition; and

(c) means coupled with said first chamber for causing insulin to be expelled from the first chamber in response to swelling of the aqueous-swellable member.

2. A pump according to claim 1 in which the aqueous-swellable member includes immobilized glucose oxidase.

3. A pump according to claim 1 in which the aqueous-swellable member comprises a pH-sensitive hydrogel membrane which swells in response to a decrease in pH by absorbing aqueous biological fluids.

4. A pump according to claim 3 in which the aqueous-swellable member includes immobilized glucose oxidase.

5. A pump according to claim 1 in which the means for causing insulin to be expelled from the first chamber comprises a second chamber.

6. A pump according to claim 5 in which said second chamber includes a valve means which permits an influx of body fluids as a function of the expulsion of insulin composition from the first chamber.

7. A pump according to claim 6 in which the second chamber is expandable.

8. A pump according to claim 1 in which the first chamber is collapsible, such that its internal volume is always substantially the same as the volume of the insulin composition it contains.

9. A pump according to claim 8 in which the means for causing insulin composition to be expelled from the first chamber comprises a second chamber.

10. A pump according to claim 9 in which said second chamber includes a valve means which permits an influx of body fluids as a function of the expulsion of insulin composition from the first chamber.

11. A pump according to claim 10 in which said second chamber is expandable.

12. A pump according to claim 11 in which said second chamber expands as a function of the expulsion of insulin composition from the first chamber.

13. A pump according to claim 12 in which the valve means of the first chamber comprises a pressure-responsive valve which permits the outflow of the insulin composition in response to an increase in pressure in the chamber and seals the chamber in response to a decrease in pressure in the chamber.

14. A pump according to claim 13 in which the valve means of the second chamber comprises a pressure-responsive valve which seals the chamber in response to an increase in pressure in the chamber, and permits an influx of body fluids in response to a decrease in pressure in the chamber.

15. A pump according to claim 14 in which the aqueous-swellable member comprises a pH-sensitive hydrogel membrane which swells in response to a decrease in pH by absorbing aqueous biological fluids.

16. A pump according to claim 15 in which the aqueous-swellable member includes immobilized glucose oxidase.

17. A pump according to claim 1 in which the aqueous-swellable member is a homopolymer or copolymer comprising monomers selected from the group consisting of n-alkyl acrylic acids and methacrylic acids, n-alkyl acrylates and methacrylates, and n-alkylacrylamids and methacrylamides, and the hydroxy- and amino-derivatives thereof.

18. An implantable pump for the delivery of insulin to a mammal in need thereof, said pump comprising an implantable, biocompatible housing of fixed volume which supports within its walls:

(a) an aqueous-swellable hydrogel member which swells in response to an increase in blood glucose level and deswells in response to a decrease in blood glucose level, said member being exposed to the body fluids which surround the pump when implanted in a mammal;

(b) means defining a first chamber for holding a pharmaceutically acceptable insulin formulation, including a valve means which permits the outflow of the insulin composition;

(c) means defining a second chamber for coupling the swelling of the aqueous-swellable hydrogel member to the first chamber such that insulin composition is expelled from the first chamber in response to swelling of the aqueous-swellable hydrogel member.

19. A pump according to claim 18 in which the aqueous-swellable hydrogel member comprises a pH-sensitive hydrogel membrane which swells in response to a decrease in pH by absorbing aqueous biological fluids.

20. A pump according to claim 19 in which the pH-sensitive hydrogel membrane includes immobilized glucose oxidase.

21. A pump according to claim 18 in which the first chamber is collapsible, the second chamber is expandable, and the second chamber expands as function of the collapse of the first chamber.

22. A pump according to claim 21 in which the internal volume of the first chamber decreases as a function of the volume of insulin composition which is expelled.

23. A pump according to claim 22 in which the total combined volume occupied by the first and second chambers within the housing is always approximately the same when the pressure in both chambers equals the pressure of the environment external to the pump.

24. A pump according to claim 23 in which the second chamber includes a pressure-responsive valve means which seals the chamber in response to an increase in pressure in the chamber, and permits an influx of body fluids in response to a decrease in pressure in the chamber.

25. A pump according to claim 24 in which the aqueous-swellable hydrogel member comprises a pH-sensitive hydrogel membrane which swells in response to a decrease in pH by absorbing aqueous biological fluids.

26. A pump according to claim 25 in which the pH-sensitive hydrogel membrane includes immobilized glucose oxidase.

27. A pump according to claim 26 in which the influx of body fluids to the second chamber is of a volume approximately equal to the volume of insulin composition expelled from the first chamber.

28. A pump according to claim 27 in which the aqueous-swellable hydrogel member includes a means adjacent to said hydrogel member and the second chamber for causing an increase in pressure in the second chamber when the hydrogel member swells.

29. A pump according to claim 28 in which said means for causing an increase in pressure in the second chamber comprises a diaphragm situated between the hydrogel member and the second chamber.

30. A pump according to claim 29 in which the second chamber comprises an elastomeric bladder.

31. A pump according to claim 28 which includes a means adjacent to both the first and second chambers whereby an increase in pressure in the second chamber causes an increase in pressure in the first chamber.

32. A pump according to claim 31 in which said means for causing an increase in pressure in the first chamber comprises a movable partition situated between said first and second chambers.

33. A pump according to claim 18 in which the aqueous-swellable member is a homopolymer or copolymer comprising monomers selected from the group consisting of n-alkyl acrylic acids and methacrylic acids, n-alkyl acrylates and methacrylates, and n-alkylacrylamids and methacrylamides, and the hydroxy- and amino-derivatives thereof.

34. An implantable pump for the delivery of insulin to a mammal in need thereof, said pump comprising an implantable, biocompatible housing of fixed volume which supports within its walls:

(a) a first chamber containing a pharmaceutically acceptable insulin composition and including a pressure-responsive valve means which permits the outflow of the insulin composition in response to an increase in pressure in the chamber and seals the chamber in response to a decrease in pressure in the chamber; and

(b) a second chamber including a pressure-responsive valve means which seals the chamber in response to an increase in pressure in the chamber, and permits an influx of body fluids in response to a decrease in pressure in the chamber;

(c) an aqueous-swellable hydrogel member which initiates an insulin pumping cycle by swelling in response to an increase in blood glucose level and terminates an insulin pumping cycle by deswelling in response to a decrease in blood glucose level, said member being exposed to the body fluids which surround the pump when implanted in a mammal and including a coupling means adjacent to at least one of said first and second chambers such that swelling of the hydrogel member causes an increase in pressure in both chambers.

35. A pump according to claim 34 in which the pressure-responsive valve in the second chamber permits the influx of body fluids in a volume approximately equal to the volume of insulin composition expelled during each insulin pumping cycle.

36. A pump according to claim 34 in which the total combined volume occupied by the first and second chambers within the housing is always approximately the same when the pressure in both chambers equals the pressure of the environment external to the pump.

37. A pump according to claim 34 in which the internal volume of the first chamber is always approximately the same as the volume of the insulin composition it contains.

38. A pump according to claim 34 in which the aqueous-swellable hydrogel member comprises a pH-sensitive hydrogel membrane.

39. A pump according to claim 38 in which the aqueous-swellable hydrogel member includes immobilized glucose oxidase.

40. A pump according to claim 39 in which the aqueous-swellable hydrogel member includes immobilized catalase.

41. A pump according to claim 39 in which the pH-sensitive hydrogel membrane is a homopolymer or copolymer comprising monomers selected from the group consisting of n-alkyl acrylic acids and methacrylic acids, n-alkyl acrylates and methacrylates, and n-alkylacrylamids and methacrylamides, and the hydroxy and amino- derivatives thereof.

42. A pump according to claim 41 in which the pH-sensitive hydrogel membrane is a copolymer comprised of AMA or DMA monomers copolymerized with DMA or DMAA monomers.

43. A pump according to claim 34 in which the aqueous-swellable hydrogel member is a homopolymer or copolymer comprising monomers selected from the group consisting of n-alkyl acrylic acids and methacrylic acids, n-alkyl acrylates and methacrylates, and n-alkylacrylamids and methacrylamides, and the hydroxy and amino- derivatives thereof.

44. An implantable pump for the self-regulated delivery of insulin to a mammal in need thereof, said pump comprising an implantable, biocompatible housing of fixed volume, which supports within its walls:

(a) an aqueous-swellable hydrogel member which initiates an insulin pumping cycle by swelling in response to an increase in blood glucose level and terminates an insulin pumping cycle by deswelling in response to a decrease in blood glucose level, said member being exposed to the body fluids which surround the pump when implanted in a mammal;

(b) a first chamber containing a pharmaceutically acceptable insulin composition and including a pressure-responsive valve means which permits the outflow of the insulin composition in response to an increase in pressure in the chamber and seals the chamber in response to a decrease in pressure in the chamber, said chamber being configured such that its internal volume is always the same as the volume of the insulin composition it contains; and

(c) a second chamber in intimate contact with said first chamber and in direct or indirect contact with said aqueous-swellable hydrogel member, such that swelling of the hydrogel member due to an increase in blood glucose level causes an increase in pressure in both the first and second chambers, said second chamber including a pressure-responsive valve means which seals the chamber in response to an increase in pressure in the chamber and permits an influx of body fluids in response to a decrease in pressure in the chamber in a volume equal to the volume of insulin composition expelled during each insulin pumping cycle,

wherein the total combined volume occupied by the first and second chambers within the housing is always approximately the same when the pressure in both chambers substantially equals the pressure of the environment external to the pump.